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M* nwbhus for generalized nsurohumoral acti- 
vatiaa lo hsart Mars lnclude dscreassd input fhtm Wbitory 
bvoneeptor afkent ves&s and increased iDput from excitatory 
afkrent vessels ari&g from arterM chemoreceptors, skeletal 
muscle nM&receptors orthe hmgs. Nat all subjects with left 
ventriadar dysfktion have ~KIVMHJ sympathetic nerve activity, 
but the magnkde of sympatho~~l activation appsars toinde= 
pendently predh4 survival. This association suggssts both a caus= 
ative msdmnhm linking sympathetic activation with adverse 
outcome and a therapeutic 0pporMiQ to hnprove the progno& 
of such patients by inbiwting central sympathetk outflow. . m sympathetic activation is not unique to heart 
faihue, and its fim&mal co- appsartobebothorgan- 
and anulitionqscitic. Sympathetic activation is present inothsr 
dkrderssuchasmiM~,cirrhosisandagingthatdo 
MltsbalEthedhIlpNJglW&dMllge!khemdMhWe.The 
adverse ekts ofadrenergic a tivation the dii myocar- 
di~maybeafunctionofthemagnitudeandthnecourseof 
Congestive heart failure has been described as a condition of 
generalized neurohumoral excitation, characterized by acti- 
vation of the sympathetic nervous and renin-angiotensin 
systems, increases in plasma vasopressin concentration, a d 
parasympathetic withdrawal (l-3). Because the magnitude 
of sympathoneural activation in congestive heart failure 
appears to predict survival (the annual mortality rate of 
patients with venous plasma norepinephrine concentrations 
900 pg/ml may exceed 70%) (3-J), the role of the sympa- 
thetic nervous ystem in its pathophysiology has received 
particular attention (1-3.6-8). Despite this attention, two 
critical questions remain unresolved: 1) Does the inverse 
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Parasympathetic 
hmeases in cardiac sympathetic nerve activity, the mechanical 
and ektrophysiologic consequences of nonuniform abnormalities 
of sympathetic hmervathm in the Ming heart and the absence! of 
spscitlc c0untervailing mecbisms present in other conditions 
also &rack&d by hased sympathe& trak. The hypothe. 
ses that activation fadrenergic drive to the dkased myocardim 
is the causative mechanism linking sympathosxdtation to adverse 
outcome and that h~terventions hat inbiiit sympathetic outtlow to 
the heart will hnprove the prognosis of patients witb congestive 
hsart Mbwe have not beg specitkally tested. Greater under- 
standh~ ofthe mechanisms re ponsiile for the heterogeneity of 
sympathetic activation in response to ventricular dysfunction, for
cardiac-specik and generakd activation of the sympathetic 
nsrvous system and for the sthuulation r suppression of counter- 
vailing mechanisms capable of resisting its adverse ekts is 
fundamental to the development of better therapies for congestive 
heart tMhu-e. 
(J Am CoU Cm&o1 19313;22[Supplement A]:72A-84A) 
relation between plasma norepinephrine concentrations nd 
prognosis indicate a causal relation between sympathetic 
activation and mortality ?, and 2) will interventions that 
inhibit sympathetic a tivity improve outcome? 
In this review I propose 1) to examine briefly manifesta- 
tions of sympathetic a tivation and parasympathetic w th- 
drawal in humans with left ventricular dysfunction, mecha- 
nisms that may be responsible for these abnormalities, and 
for the potential dverse ffects of adrenergic activation on 
the diseased myocardium and peripheral circulation i con- 
gestive heart failure, and 2) :o develop the following con- 
cepts: a) not all subjects with left ventricular dysfunction 
have increased sympathetic nerve activity; b) sympathetic 
activation is not unique to heart failure; and c) many of the 
mechanisms contributing tosympathetic a tivation i heart 
failure are functionally rather than structurally impaired and 
are potentially amenable to modulation. I will conclude with 
the proposal that activation of adrenergic drive to the diiased 
myocardium ay be the causative mechanism linking sym- 
pathoexcitation and this adverse outcome. If so, future thera- 
peutic interventions should specifically address the hypothesis 
that inhibiting sympathetic drive to the heart will improve 
the prognosis of patients with congestive heart failure. 
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Pigure 1. Assessment of sympathetic and 
parasympathetic fun tion in humans. Sympa- 
thetic function: arterial (A) or venous (V) 
plasma norepinephtine (PNE) and epineph- 
rine (PE) concentrations (opper left); sympa- 
thetic nerve traific to muscle (MSNA) or skin 
(lower left); total body norepinephrine 
([3H]NE) spillover or regional norepinephrine 
spillover across the heart (A = aorta or arte- 
rial; CS = coronary sinus) (upper right!, kid- 
ney (lower ight) or leg (lower left); spectral 
analysis of heart rate variability (SA-HRV) 
(upper right). Parasympathetic function 
(upper tight): bradycardic response to phe- 
cylephrine (baroreflex sensitivity; BRS); 
spectral nalysis of heart rate variability (SA- 
HRV). 
Sympathetic and Parasympathetic Nervous 
Systems in Heart Failure 
Sympathetic Nervous System 
Assessment of sympathetic function in humans. Efferent 
postgaqglionic sympathetic nerve traflic may be assessed 
directly in humans by inserting microelectrodes into uper- 
ficial nerves innervating muscle orskin (9) or indirectly by 
recording potential effector esponses to the neurally re- 
leased norepinephrine, such as heart rate j blood pressure or 
regionai blood flow and vascular resistance, orby quantitat- 
ing venous or arterial catecholamine concentrations (10,l I), 
norepinephrine spillover into plasma (12) or heart rate vari- 
ability (13-15) (Fig. 1). 
Each of these methods assesses different aspects of 
sympathetic function and has its advantages and limitations. 
The latter should be considered carefully when interpreting 
information acquired with ese techniques. Any potential 
link between sympathetic a tivity and hemodynamics wii1 
be particularly tenuous in heart failure as a result of altered 
receptor esponsiveness, cardiac and vascular structural 
alterations and concurrent activation of other vasoactive 
systems. 
Norepinephrine concentrations can be determined simply 
and relatively inexpensively, but the values obtained have 
several shortcomings that limit their lusefulness as measures 
of sympathetic nerve t af8c in humans (10,ll). Only a small 
fraction of neurally released norepinephrine appears in 
plasma, and that which is measured does not reflect neuro- 
transmitter release, but rather the balance between orepi- 
nephrine spillover into plasma and its clearance (12,16). 
Values are weighted toward regional (for exaaple, forearm) 
neurotransmitter spillover upstream from the sampling loca- 
tion (Fii. 1) (10,12). Because the sympathetic nervous ys- 
tem is capable of differential outflow, it should not be 
assumed that plasma norepinephrine concentrations mea- 
sured from the antecubital vein provide an accurate estimate 
of sympathetic t&Tic to other hemodynamically important 
vascular beds (10-12). The issue of c!eaace is perhaps 
most important in the context of heart failure. Becmse 
norepinephrine cl arance is a function of regional b ood flow 
and inversely related to cardiac output (12), the interpreta- 
tion of any increase inplasma norepinephrine concentrations 
in heart failure will be ambiguous. Does it represent in- 
creased norepinephrine release or markedly impaired clear- 
ance in patients with poor left ventricular function? 
To address this question, Esler et al. (12) developed a 
radiotracer method of assessing total body norepinephrine 
spillover as an indirect but close approximation f neural 
norepinephrine release in conscious humans. By adapting 
this technique to estimate regional (that is,organ-specific) 
norepinephrine spillover, these investigators (12,17) were 
also able to determine whether sympathetic a tivation in 
heart failure is generalized or directed specifically toward the 
heart, kidney or other vascular beds. 
The major strength ofthe microneurographic technique is
that it permits direct quantitation f sympathetic nerve tiring 
and its reflex control (9.18). Recordings are limited to 
superficial nerves, innervating muscular or cutaneous vas- 
cular beds. Because these nerves have diierent firing char- 
acteristics under basal conditions and in response todiffer- 
ent stimuli, muscle sympathetic nerve burst frequency 
(influenced primarily by changes in baroreceptor afferent 
discharge) need not represent thing rates in other sympa- 
thetic nerves (9,lO). It is therefore worth noting that Wallin 
et al. (19) recently obtained evidence in normal subjects at 
rest that interindividual diierences in muscle sympathetic 
nerve discharge and cardiac norepinephrine spillover are 
proportional toeach other. Their findings are consistent with 
the concept that a common mechanism influences the 
strength of sympathetic discharge to he heart and skeletal 
muscle. 
The possibility that spectral analysis of heart rate vati- 
ability might provide a noninvasive estimate of sympathetic 
drive to the heart has stimulated considerable interest (Big. 
1). However, there is as yet no clear consensus as to the 
optimal repr= _ ,sea&n of c&iac symphetic nerve t.diC 
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by this method (14,15,20-22). Current analytic algorithms 
are limited by the need for heart rate variation for their 
application; such variation is lost in severe decompensated 
heart failure where sympathetic drive is highest, yet heart 
rate is fixed. 
Evidence for gemahed qmpahmural acthtiOn in 
heart hike. Plasma norepinephrine concentrations sam- 
pled uring supine rest are elevated in patients with asymp- 
tomatic left ventricular dysfunction a d increase further with 
the progression t  overt congestive h art failure (1,3,23). At
this later stage, total body norepinephrine spillover is on 
average double that of control subjects and norepinephrine 
clearance r duced by about athird (Fig. 2) (17). 
Are these changes due to generalized increases in central 
sympathetic outflow or selective activation f sympathetic 
discharge to specific vascular beds? Certainly, the presenta- 
tion of the patient insevere decompensated congestive h art 
failure suggests generalized sympathetic activation: tachy- 
cardia, tachypnea, diaphoresis, pallor, agitation and renal 
sodium retention. Biochemical and microneurographic evi- 
dence of increased sympathetic outllow to the kidneys, 
heart, skeletal muscle and adrenal glands confirms this 
clinical impression. 
In normal subjects, approximately 25% of total body 
norepinephrine spillover arises from the kidney and about 
2% from the heart (12). These two organs contribute approx- 
imately 60% of the increase in the total body rate of 
appearance of norepinephrine in plasma incongestive h art 
failure: renal norepinephrine spillover increases 2- to 3-fold 
and cardiac norepinephrme spillover >lO-fold (Fii. 2) 
(12,17). Norepineptine spillover into the leg circulation also 
doubles (24). Because the radiotracer kinetic technique 
quantitates he rate at which neuronally released norepi- 
nephrine appears in plasma rather than sympathetic nerve 
tralRc or the rate of release of the neurotransmitter from
sympathetic nerve ndings, ome of the increased spillover 
could be attributed to enhanced prejunctional modulation f 
neurotransmitter rel ase by epinephrine (25) or augiotensin 
(261 or by decreased norepinephrine extraction within the 
neurovascular j nction (12,27). This ambiguity was resolved 
by investigators (28,29) who obtained direct microneuro- 
graphic evidence that efferent muscle sympathetic burst 
frequency is increased in cowestive heart failure @ii. 3) and 
Figure 2. Total body, cardiac and renal norepineph- 
rine spillover and norepinephrzne clearance from 
plasma in patients with congestive h art failure 
(CHF) and control subjects (CL +p < 0.02; **p c 
0.002. 1 =liters. Adapted, with permission f the 
Au&can Heart Association, from Hasking et al. 
WI. 
correlates positively with plasma norepinephrine concentra- 
tions. 
Epinephrine concentrations are increased in severe heart 
failure, denoting heightened adrenal sympathetic nerve ac- 
tivity and medullary catecholamine rel ase (3). Increased 
plasma concentrations provide the substrate for its neuronal 
uptake and incorporation i to sympathetic vesicles along 
with norepinephrine (30). Esler et al. (30) have documented 
cardiac epinephrine spillover, averaging 2 ng/min or 2% of 
the corresponding orepinephrine spillover, in untreated 
congestive h art failure (but not in healthy volunteers atrest) 
and hiiher levels of neuronal epinephrine release from their 
gut, liver, lungs and kidneys. Approximately 25% of their 
total plasma epinephrine appearance rate was due to regional 
overflows from these organs. This observation demonstrates 
that epinephrine can assume a neurotransmitter role in heart 
failure, in addition to its traditional ction as a circulating 
hormone (31). This transformation may have important 
functional consequences in this condition: as a humoral 
agent, he predominant effect of epinephrine is postjunction- 
ally mediated vasodilation, whereas as a wtransmitter, its 
predominant effect appears to be vasownstriction mediated 
by stimulation of prejunctional beb-adrenergic receptors 
that act to facilitate norepinephrine release (25). 
Parasympathetic Nervous System 
The parasympathetic control of heart rate may be as- 
sessed by quantitating the reflex bradycardic response tothe 
pressor stimulus of phenylephrine (13) or by analysis of heart 
rate and its variability in the time (13) or frequency (14) 
domain (FE. 1). Each of these methods conilrms the initial 
demonstration by Eckberg et al. (32) of impaired parasym- 
pathetic ontrol of heart rate in heart failure (20-22,33). 
Although low heart rate variability appears to be an inde 
pendent risk factor for mortality after myoca&al infarction 
(34), the prognostic importance of this abnormality in pa- 
tients with heart failure has not been clearly established. 
Similarly, the pathophysiologic implications of defective 
parasympathetic control of heart rate have not been fully 
investigated. It has been proposed that alterations in the 
parasympathetic component of heart rate variabiity spectra 
merely reflect greater sympathoexcitation in such patients 
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Figure 3. Representative tracings 
of the electrocardiograms @per 
tradugs) and mean voltage neuro- 
grams of muscle sympathetic 
nerve activity (lower tracings) in 
three normal subjects (left) and 
three patients with heart failure 
(right). Adapted, with permission 
of the American Heart Associa- 
tion, from Leimbach et al. (2Q 
4 01 oum1s=9 +&Age 27 
(15). However, these are probably independent as well as 
interdependent al erations. They are independent in that 
impaired parasympathetic control of heart rate may precede 
sympathetic a tivation, as has been reported insubjects with 
idiopathic dilated cardiomyopathy (33). They are interdepen- 
dent in that withdrawal of the restraining influence of ace- 
tylcholine on norepinephrine release (35) may explain why 
the relative increases in transcardiic norepinephrine spill- 
over in heart failure are so much greater than those observed 
across other vascular beds, such as the kidney orthe leg (17) 
(Fig. 3 and 4). 
Mechanisms for Generalized Sympathetic 
Activation and Parasympathetic Withdrawal in 
Heart Failure 
Generalized sympathetic activation and parasympathetic 
withdrawal in heart failure have been attributed to alter- 
ations in inhibitory and excitatory infhrences on brainstem 
vasomotor neurons. These mechanisms are illustrated in 
Figure 5. The contribution of impaired inhibitory barorecep 
tor reflex mechanisms to these abnormalities of autonomic 
reflex control has been reviewed in depth by Thames et al. 
(36). ABerent inputs from carotid sinus and aortic arch 
“arterial high pressure” and the cardiopulmonary “low 
pressure” mechanoreceptors a ethe principal inhibitory 
infhrences on sympathetic oudlow; discharge from arterial 
chemoreceptors and muscle “metaboreceptors” are the 
major excitatory inputs. The vagal limb of the baroreceptor 
heart rate reflex is also responsive to arterial baroreceptor 
atferent input. The integrated response to these competing 
influences innormal subjects at rest may be characterized as 
a relatively low sympathetic discharge nd relatively high 
heart rate variability. Compensatory vagal and sympatho- 
Figure 4. I&al; + SE values for total body and regional norepineph- 
rine spillover into plasma in 20 patients with congestive heart 
failure, 50 patients with essential hypertension a d 35 patients with 
cirrhosis. Sign&ant increases from reference values ohtained from 
28 healthy subjects (100%) are indicated by *p c 0.05 and **p < 
0.01. Reproduced, with permission f the American Heart Associ- 
ation, from Esler et al. (12). 
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Figure 5. Mechanisms for generalized sympa- 
thetic activation and parasympathetic withdrawal 
in heart failure. Under normal conditions (top 
panel) inhibitory (-1 inputs from arterial and 
cardiopulmonary bamreceptor tierent nerves 
are the principal influence on sympathetic out- 
flow. Parasympathetic control of heart rate is also 
under potent arterial baroreflex control. Efferent 
sympathetic rafiic and arterial catecholamines 
are low and heart rate variability high. As heart 
failure progresses (bottom panel) inhibitory input 
from arterial and cardiopulmonary receptors de- 
creases and excitatory (+) input increases. The 
net response to this altered balance includes a
generalized increase insympathetic nerve trtic, 
blunted parasympathetic and sympathetic control 
of heart rate and impairment of the reflex sympa- 
thetic regulation ofvascular resistance. Anterior 
wall ischemia has additional excitatory effects on 
efferent sympathetic nerve tralTtc. See text for 
details. Ach = acetylcholine; CNS = central 
nervous ystem; E = epinephrine; Nat = so- 
dium; NE = norepinephrine. 
neural responses toacute perturbations i  blood pressure are 
appropriate and brisk (Fig. 5, top panel). 
Asymptomatic left ventricular dysfunction and its pro- 
gression to overt congestive h art failure disturb this balance 
(Fig. 5, bottom panel). As the principal stimuli to arterial 
baroreceptor tierent discharge (tbat is, systolic blood pres- 
sure, pulse pressure and the rate of rise of blood pressure) 
become blunted and as the sensitivity of arterial, atrial and 
ventricular mechanoreceptors  stretch diminishes, inhibi- 
tory input from arterial and cardiopulmonary receptors will 
decrease (2,37-39). In decompensated heart failure, excita- 
tory input, ordiiy quiescent, may arise from arterial 
chemoreceptors, skeletal muscle metaboreceptors and the 
lungs (37). Central regulation of parasympathetic outflow is 
also attenuated (40). The net response to this shift in the 
balance between inhibitory and excitatory atferent input 
includes ageneralized increase inbasal sympathetic outflow, 
parasympathetic withdrawal, blunted reflex parasympathetic 
and sympathetic control of heart rate and impairment of the 
reflex sympathetic reguhtion of vascular resistance (2,18,37). 
Heterogeneity of Sympathetic Activation in 
Heart Failure 
Nonetheless, many individuals with left ventricular dys- 
function lack evidence for sympathetic a tivation (1,4,33, 
41). Viquerat et al. (42) documented arterial norepinephrine 
concentrations within eir normal range in about one-third 
of their subjects with heart failure. The initial Studies of Left 
Ventricular Dysfunction (SQLVD) report (23) on baseline 
neurohormonal data described venous plasma norepineph- 
rine concentrations below the median value for control 
subjects in -25% of patients recruited o the asymptomatic 
arm and in about 15% of patients recruited to the treatment 
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Table 1. Some Potential Explanations of Variations in 
Sympathetic Werve .4ctivity in Patients With Heart Failure 
Patient age 
Stage of disease 
Severity of disease 
Therapeutic interventions 
Sympathoexcitatory: sodium restriction, diuretic drugs, nonspecific 
vasodilators 
Sympathoinhibitory: digitalis glycosides, beta-adrenergic antagonists, 
converting enzyme inhibition, physicai conditioning 
Coexisting disurders 
Sympathoexcitatory: ischemic heart disease, sleep-related breathing 
disorders 
Sympathoinhibitory: autonomic neuropathy 
arm of this study. The majority of the young subjects with 
asymptomatic dilated car iomyopathy that we have studied 
have muscle sympathetic nerve activity and plasma norepi- 
nephrine concentrations similar to those of age-matched 
normal volunteers (41). 
Why is there such intersubject variation i  sympathetic 
nerve activity in heart failure? Several factors could contrib- 
ute to these variations insympathetic traflic in patients with 
left ventricular dysfunction. Some of the more &ious 
examples appear in Table 1. 
Stage and severity of disease. Abboud et al. (43) described 
three phases of autonomic disturbance in heart failure. In the 
early stage, decreased cardiac output activates the sym- 
pathoadrenal and renin-angiotensin systems r flexively. In 
the middle stage, compensatory h pervolemia and cardiac 
enlargement stimulate baroreceptor afferent vessels, causing 
reflex suppression or normalization of sympathetic nerve 
activity. In the final stage, the restraining influence of 
cardiac and arterial baroreceptor tierent vessels on the 
sympathetic nervous ystem and the renin-angiotensin sys- 
tems is impaired, resulting in generalized neurohumoral 
activation (Fig. 5). 
acutely or chronically through reflexive mechanisms, inde- 
pendent of any coexisting left ventricular dysfunction 
(39,44). Efferent sympathetic nerve activity could increase 
or decrease, &pending OG the nature and anatomic lo ation 
of this insult. Prior myocardial infarction will nterrupt the 
course of mechanoreceptor input to vagal tierents with 
inhibitory effects on sympathetic outfiow (44,45) (Fii. 5). 
Although not depicted in Figure 5, anterior wall &hernia 
elicits reflex sympathoexcitation by stimulating sympathetic 
aRerent nerves (39,46-49) and, if arterial blood pressure 
decreases during this ntervention, by unloading sinoaortic 
baroreceptors (50), whereas i chemia involving-the infero- 
posterior wall of the left ventricle vokes a depressor reflex 
(39,47,48,51,52). Thus, it may not be appropriate to present 
data on ischemic and idiopathic dilated cardiomyopathy as if
they arose from a common mechanism. Much of the evi- 
dence for increased sympathetic nerve t&c to muscle in 
congestive heart failure arises from studies of older patients 
with ischemic heart disease (28,29). Contrary evidence from 
young subjects with compensated idiopathic dilated cardio- 
myopathy (33,41) suggests that he cause of heart Wure may 
alsc influence the time course or magnitude of sympathetic 
activation i patients with lefi ventricular dysfimctioo and, 
possibly, its adverse effects on the failing heart. For exam- 
ple, Bristow et al. (53) have described important functional 
differences in components of the beta-adrenergic eceptor-G 
protein-adenylate cyclase omplex between ischemic and 
idiopathic dilated cardiomyopathy. 
Ferguson et al. (29) have quantitated disease severity 
with the use of balloon-tipped thermotiution catheters in
their study patients. They identified reduced cardiac perfor- 
mance and increased cardiac filling pressures as character- 
istics of patients with increased muscle sympathetic nerve 
activity. In contrast to Viquerat et al. (42), wh3 did not 
uncover any convincing relation between arterial norepi- 
nephrine concentrations and the hemodynamic status of 
their patients, sympathetic burst fi=equency in the study of 
Ferguson et al. (29) was inversely related to lefi ventricular 
stroke work index and stroke volume index and directly 
related to pulmonary artery mean and diastolic pressures. 
The latter observation is particularly intriguing because it
raises the possibiity hat mechanisms capable of sensing the 
severity of heart failure are preserved at this stage of the 
disorder @beit responding paradoxically) and are poten- 
tially amenable tomodulation. 
&&sting disorders: is&emie heart disease. Myocardial 
infarction or ischemia can influence sympathetic outffow 
Coexisting disorders: obstructive sieep apnea. Sympa- 
thetic withdrawal during sleep typically results in a decrease 
in blood pressure of20% to 25% from average waking levels 
(54-56). Heart failure is associated with briefer sleep dura- 
tion, interrupted sleep and attenuation f the awake-asleep 
difference in blood pressure (57,58). Many patients with 
congestive heart failure also suffer from sleeprelated 
breathing disorders, includmg obstructive sleep apnea (57). 
Apnea, hypoxia nd hypercapnia, which develop recmrently 
in obstructive sleep apnea, can cause profound increases in
muscle sympathetic nerve activity (59-61). Such distur- 
bances in breathing during sleep will adversely alter after- 
load in the failing heart by generating extreme negative 
swings in intrathoracic pressure (57) and by preventing the 
normal nocturnal reductions in sympathetic drive and blood 
pressure (56j. These noctlurnal abnormalities may stimulate 
the development of left ventricular hypertrophy (62). Obser- 
vations from our own (41) and other (63) laboratories raise 
the possibility hat apneic episodes during steep t$W a 
sustained non-barorefiex-mediated ncrease incentral sym- 
pathetic outiow that carries over into the daytime when 
subjects are awake and breathing spontaneously. unremit- 
ting exposure by day and at night o such sympathoexcita- 
tion could contribute synergistically to the dcve!opment or 
aggravation of congestive heart failure, but would not be 
responsive toconventional pharmacologic treatment. 
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Table 2. Potential Adverse Effects of Sympathetic Activation in 
Heart Riilure 
cardiac 
Decreased betbndrenergic e eptor responsiveness 
Myowe hypertrophy 
Myocyte necrosis and fibrosis 
Nonuniform depletion ofnorepinephrine stores 
Nonuniform &struftiw of sympathetic innervation 
Arrhythnriap 
Imp&d diastolic function 
Impaired systolic function 
Renal 
Increased tubular reabsorption of sodium 
Activation of &tkangiotensio system 
Increased renal vascular resistance 
Attenuated response tonatriuretic factors 
vasculiu 
Neurogenic vasoconstriction 
Vascular hypertrophy 
Adverse l#ects of Adrenergic Activation on the 
Diseased Myocardium and Per&heral Circulation 
AIIY supportive ffect of this generalized increase in 
central sympathetic outflow on the heart and peripheral 
circulation i congestive failure is eventually superseded by 
a number of functional organ-specific consequences with 
potentially adverse implications (Table 2, Fig. 5). 
Myoerudium. Daly and Sole (7) reviewed the time course 
of changes in myocardial sympathetic nnervation and 
catecholamine content with the initiation and progression 
of experimental heart failure. In the hamster model of 
dilated cardiomyopathy, early increases in cardiac nore- 
pinephrine turnover, tyrosine hydroxylase and dopamine 
beta-hydroxylase ctivity and cardiic dopamine stores are 
followed by depletion of myocardial norepinephrine content 
and destruction ofsympathetic nerve terminals. Other con- 
tributors to this symposium have discussed in detail the 
adverse ffects of adrenergic drive on cardiac structure and 
function. These include downregulation of myocardial betar- 
adrenergic receptor number, decreased beta-adrenergic 
responsiveness to endogenous or exogenous agonists (64), 
trophic and toxic effects on cardiac myocytes (65), exacer- 
bation of arrhythmias predisposing to sudden death and 
impairment of ventricular diastolic and systolic function 
(Table 1). Daly and Sole (7) placed particular emphasis on 
the topography of altered myocardial norepinephrine co - 
tent and sympathetic innervation i experimental heart fail- 
ure; these investigators postulated that nonuniform distri- 
bution of these derangements would disturb the temporal 
coordination f mechanical contraction and relaxation, alter 
the dispersion f refractoriness and the duration and contig- 
uration of the cardiac action potential and consequently 
exacerbate any underlying mechanical orelectrophysiologic 
dysfunction i such patients. 
paipheral &culatlon. Excessive sympathetic drive to 
the periphery can exacerbate he hemodynamic derange 
ments of heart failure by increasing both preload and after- 
load (Fig. 5). For example, levated elferent renal sympa- 
thetic nerve activity will exacerbate congestion by activating 
the renin-angiotensin system, stimulating tubular eabsorp- 
tion of sodium and water, decreasing renal blood Uow and 
glomerular f&ration rate and blunting the renal responsive- 
ness to atrial natriuretic peptide (2,66,67). Augmented ad- 
renergic drive to muscle will sustain afterload at inappropri- 
ately high levels, whereas secondary hypertrophy of smooth 
muscle in resistance vessels will ampliiy neurogenic vaso- 
constrictor responses to sympathetic input (7,68,69). Reduc- 
tions in muscle blood flow by these mechanisms below levels 
required to meet local metabolic demands may increase 
sympathetic outflow reflexively, particularly during exer- 
cise, by stimulating excitatory metaboreceptor afferents 
(Fig. 5) and possibly contribute to the impaired functional 
capacity of such patients (2,69). 
In summary, there are many cardiac and peripheral 
mechanisms by which sympathetic activation could ad- 
versely inlluence prognosis in heart failure. However, any 
attempt to establish a causal relation between sympathetic 
activation and mortality on this basis must contend with e 
awkward observation that sympathetic activation is not 
unique to heart failure, but is present in other disorders that 
do not share its poor prognosis. 
Other Conditions of Generalized 
Sympathetic Activation 
Sympathetic excitation and p rasympathetic w thdrawal 
are not specific to heart failure: There is biochemical or 
microneurographic evidence, or both, of increased sympa- 
thetic outflow to the kidneys, heart, skeletal muscle and 
adrenal glands in young subjects with borderline and mild 
essential hypertension (12,70-73), in patients with cirrhosis 
and ascites (12,74), in subjects with obstructive sleep apnea 
even when studied while awake (63) and in healthy elderly 
persons (70,75) (Fig. 6). Hypertension and aging are also 
characterized by impaired parasympathetic control of heart 
rate (76). Cardiac and renal norepinephrine spillover are 1.5 
to 3-fold higher in young subjects with hypertension than in 
age-matched normotensive control subjects (12) (Fig. 4). 
Renal norepinephrine spillover is increased threefold in 
patients with cirrhosis, whereas cardiac norepinephrine 
spillover is five to seven times higher than in control subjects 
(12) (Fii. 4). Indeed, subjects with cirrhosis and ascites 
display aprofile of generalized neurohumoral activation ot 
unlike that of the patient with heart failure (74,77): Atrial 
natrhrretic factor is increased (78), the heart rate is _ ?pid, 
and varies little, and increases in muscle sympathetic nerve 
activity correlate positively with elevated venous norepi- 
nephrine and epinephrine concentrations and with plasma 
renin activity (74). 
The reflex and central mechanisms responsible for in- 
creased sympathetic outflow and parasympathetic with- 
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Figure 6. increased muscle sympa- 
thetic nerve activity (MSNA) is not 
specific to heart failure. Reproduc- 
tions of 40-s egments onthe electro- 
cardiogram (ECG) and mean voltage 
neurograms of muscle sympathetic 
nerve activity in four of our subjects 
with other conditions ofsympathetic 
activation: a healthy elderly P70 
years) subject (upper Mt) and three 
young (~40 years) subjects with, re- 
spectively, mild hypertension, sleep 
apnea @udied while awake) and cir- 
rhosis with ascites. 
MSNA 
Sleep Apnea 
MSNA 
drawal differ in each of these conditions, yet the integrated 
neural output received by important target organs is quah- 
tatively similar (that is, there is no characteristic neural 
signature that is specific for each of these particular patho- 
geneses) (Fig. 6). This observation raises two interesting 
questions. First, if increased central sympathetic outflow is 
common to each of these conditions, why are its potential 
adverse effects in heart failure (Table 2) not shared by other 
conditions characterized by sympathetic activation? The 
pathologic consequences of this nonspecific neural stimulus 
appear to be condition- and organ-specific. Young subjects 
with hypertension, healthy elderly patients and patients with 
cirrhosis and ascites diBer greatly in their hemodynamic 
profiles and display a wide range of cardiac, renal and 
vascular responses tothe burden of increased sympathetic 
outflow. For example, th  early “hyperadrenergic” stage of 
essential hypertension in young subjects is characterized by
increased cardiac output (79,80) and despite increases in 
their arteriolar waMumen ratio, which should enhance vas- 
cular responsiveness to norepinephrine and other vasocon- 
strictors @I), bmchiai artery blood ffow is increased through 
a be&-adrenergic mechanism (81). Patients with cirrhosis 
and ascites tend to have increased rather than decreased 
cardiac output, peripheral vasodilation rather than constric- 
tion and blunted vascuhrr responsiveness to norepinephrine 
(82-85). These hemodynamic patterns are quite different 
from those seen in patients with ventricular dysfunction. 
Second, if there is a causal relation between sympathetic 
activation and mortality, why is it not manifest inthese other 
conditions? Increased plasma norepinephrine concentra- 
tions, for example, do not confer the same dim prognosis on 
the healthy elderly or persons with primary hypertension as
they do in patients with heart failure. 
Several factors could account for such diversity: The 
magnitude of sympathetic activation. organ-specific re- 
sponses to increased adrenergic drive, and the presence or 
absence of amplifying or opposing forces, unique to each 
condition. 
Mild Hypertensioa 
I 
I J 
Cirrhosis With Ascites 
Ctrgau-specik respoums. Three important card&-specific 
factors are worth noting. First, and perhaps most fundamen- 
tal, is that regardless of the etiology of ventricular dysfunc- 
tion and in contrast o these other conditions, both the 
primary stimulus to and the target of increased cardiac 
sympathetic drive is a diseased myocardium. Second, the 
increase in cardiac norepinephrine spillover relative to that 
in other vascular beds appears to be greater in congestive 
failure than in cirrhosis or primary hypertension (12) (Fig. 4). 
Reasons for this observation have not been fully elucidated, 
but could include more intense neural drive to the heart, 
greater withdrawal of the inhibitory influence of a.cetylcho- 
line (35) and augmentation of the faciiitatory influence of 
epinephrine (3,30,3 I ,70) on cardiac norepinenhrine release 
and possibly (this issue remains controversial) decreased 
neuronal norepinephrine upiake (12,27,86&U). Third, the 
effects of prolonged intense adrenergic stimulation on myo- 
cardial norepinephrine stores and sympathetic nerve termi- 
nals are heterogeneous (7). The diseased heart, with its 
altered geometry and patchy distribution of fibrosis and 
necrosis, will be particulariy sensitive to any nonuniform 
destruction of sympathetic or parasympathetic innervation. 
Such pathologic inhomogeneity may have profound mechan- 
ical, electrophysiologic and prognostic mplications for pa- 
tients with heart failure (7). 
The differing vascular esponses to increased muscle 
sympathetic a tivity in congestive heart failure, mild hyper- 
tension and cirrhosis, described earlier, reinforce the con- 
cept that condition- or organ-specific actors may also am- 
plify or oppose neuroeffector ransduction f this increased 
adrenergic drive. Neurogenic vasoconstriction Can be ampli- 
fied geometrically b structural changes inresistance v ssels 
(68) and opposed by potent endothelially mediated vasodi- 
Iation (88). The latter mechanism is impaired in both byper- 
tension (89) and heart failure (90,91) and may be augmented 
in cirrhosis (92). On the basis of these observations, one 
could propose that interventions that improve ndothehalIy 
mediated vas&on might benefit patients with congestive 
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heart failure by countering the vasoconstrictor response to 
their increased sympathetic drive. 
The response ofthe kidneys to increased renal sympa- 
thetic nerve activity (Fig. 5) appears tobe more homoge- 
neous (66). We have documented an inverse relation be- 
tween muscle sympathetic nerveactivity and both the 
f?actional excretion ofsodium (74) and the natrhuetic re- 
sponse to a 2-h infusion of atrial natrImtic peptide (67) in 
patients with cirrhosis and ascites. These derangements in 
renal function and responsiveness to atrial natrhuetic pep- 
tide appear common toboth cirrhosis and congestive h art 
failure (67,93-95). However, increased renal sympathetic 
nerve activity alone cannot account for these changes; renal 
norepinephrine spillover isincreased in young subjects with 
essential hypertension (12) (Fii. 4), but they do not sulfer 
from edema or ascites as a consequence. 
In summary, neither the adverse effects detailed in Table 
2 nor the poor prognosis of patients with heart failure can be 
attributed xclusively to increased central sympathetic out- 
llow. The functional consequences of sympathetic activation 
appear to be condition- and organ-specific. O  these, the 
adverse effects of intense cardii sympathetic activation  
a diseased myocardium may be most important, and inter- 
ventions that preferentially ttenuate adrenergic drive to the 
heart may be of particular benefit. Thus far, the hypothesis 
that inhibiting efferent sympathetic nerve activity will im- 
prove the prognosis of patients with congestive h art failure 
has not been tested irectly. 
Modulation of Sympathetic Activity in 
Heart Failure 
The only drugs hown to reduce the incidence of death in 
congestive h art faihue thus far are converting enzyme 
inhibitors and nonspecific vasodilators (96-99), but the 
mortality r3te irl treated patients remains disappointingly 
hii. In those with severe heart failure enrolled in the 
Cooperative North Scandinavian Enalapril Survival Study 
(CONSENSUS) (97), the 6-month mortality rate was 48% in 
the placebo-treated group and 29% in the nal@-treated 
group (97). The impact of converting enzyme inhibition on 
survival of patients with less evere xpression f their 
congestive h art failure has been modest: iuthe SOLVD 
Treatment Study (9g), the mortality rate was 39.7% in the 
conventionally treated group and 35.2% in the enalapril- 
treated group (that is, mortality benefit was provided toonly 
4.51100 patients after 41 months of treatment, and in the 
SOLVD Prevention Trial (MO), converting enzyme inhibi- 
tion attenuated heprogression of asymptomatic left ventric- 
ular dysfunction to congestive h art failure but had no 
significant effect on mortality. .4lthough t e positive effects 
of long-term converting enzyme inhibition on survival may 
be greatest in subjects with highest norepincphrine w cen- 
trations (3,5), the SOLVD neurohumoral substudy data 
presented by Benedict e al. (101) elsewhere in this sympo- 
sium do not reveal any short-term or long-term effect of 
angiotensin-converting nzyme inhibition with enalapril on 
mean values for plasma norepinephrine concentrations. 
Thus, it is not clear whether sympathoinbibition is one of the 
mechanisms by which converting enzyme inhibition i ter- 
rupts disease progression r improves the prognosis of
asymptomatic or symptomatic patients. 
The SOLVD, CONSENSUS and other ecent trials have 
had a major positive impact on our understanding a d 
management of congestive h art failure. These trials have 
also emphasized theneed to develop additional interventions 
to improve the poor prognosis, even after treatment, of hese 
patients. Packer (8) recently summarized thelimitations of 
early attempts to antagonize the peripheral effects of neu- 
rally released norepinephrine. Thealpha-l antagonist pra- 
zosin, for example, has no demonstrable eff ct on mortality 
(96) and, until recently clinicians have been reluctant to
prescribe beta-adrenoceptor antagonists forsuch patients 
out of wncem that they will further impair contractile 
function. The principal drawback of this adrenoceptor an- 
tagonist approach is its limited objective, which is to shield 
the heart, kidney and peripheral vascadature from the poten- 
tially harmful eRects of neurally released norepinephrine 
rather than to attenuate sympathetic outllow to these organs. 
It is diicult to maintain a consistently effective shield with 
long-term treatment and, perhaps more important, the neu- 
roeffector response toother neurotransmitters released by 
noradrenergic nerves innervating the heart will not be 
blocked by these antagonists. One such neurotransmitter is 
neuropeptide Y, apotent inhibitor of efierent vagal neuro- 
transmission (102) and a wronary and peripheral vasocon- 
strictor with a more sustained duration ofaction than that of 
norepinephrine (103). 
To attain additional benefit, it may be necessary to
attenuate drenergic drive directly by developing and apply- 
ing interventions that attenuate central sympathetic outllow 
or norepinephrine synthesis (104) or release. Neural norepi- 
nephrine r lease may be reduced by several distinct mech- 
anisms: by augmention f inhibitory baroreceptor input, 
suppression of excitatory influences, inhibition of sympa- 
theric tral8c entrally and prejunctional inhibition ofneuro- 
transmitter r lease (Pi. 7). 
Obviously, the lirst approach would not be feasible if 
reflex sympathetic activation due to baroreceptor dysfunc- 
tion were an inevitable and irreversible consequence of heart 
failure. However, evidence from several sources indicates 
that he restraining influence ofinhibitory arterial nd car- 
diopulmonary mechanoreceptor tierents on sympathetic 
outllow is suppressed, rather than irreversibly damaged in 
congestive h art failure. For example, cardiac unloading 
with lower body negative pressure can evoke a reflex sym- 
pathoinhibitory response in some patients with congestive 
failure: this paradoxic observation has been attributed to a 
decrease in left ventricular end-diastolic volume and wall 
stress, a consequent i crease inleft ventricular fractional 
shortening and an inotropically mediated increase in ventric- 
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Figure 7. Attenuation of sympathetic outflow 
in heart failure. Potential mechanisms include: 
1) augmenting inhibitory baroreceptor input by 
sensitization r stimulation f arterial and cardio- 
pulmonary baroreceptor afferents; 2) decreasing 
excitatory afferent input from arterial chemore- 
ceptors, keletal muscle or lungs: 3) central inhi- 
bition of sympathetic outiow; 4) inhibition of 
ganglionic neurotransmission; a d 5) prejunc- 
tional inhibition of norepinephrine or pinephrine 
release. In addition, the neuroegector response 
to increased adrenergic drive can be blocked by 
alpha- and beta-adrenoceptor antagonists. Ab- 
breviations as in Figure 5. 
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uiar mechanoreceptor discharge (43,105). The arterial 
baroreflex control of heart rate also appears to be function- 
ally rather than structurally impaired because it can be 
restored by treatment of decompensated h art failure by bed 
rest, salt restriction, diuretic drugs and vasodilators ( uch 
treatment may also blunt excitatory influences on sympa- 
thetic outflow) (106), by reversal of canine heart failure (107) 
or by heart ransplantation n humans (108). Nonpharmaco- 
logic approaches should also prove ffective: the benefits of 
long-term exercise training of selected subjects with conges- 
tive heart failure include reduction of total body norepineph- 
rine spi!lover and normalization of the parasympathetic and 
sympathetic control of heart rate variability (109). Atria1 
natriuretic peptide, which inhibits sympathetic outflow in 
normal subjects through either a central or a ganglionic 
mechanism (1lo), also has inhibitory effects on norepineph- 
rine and epinephrine release that are not attenuated in
experimental canine heart failure (111); its potential sym- 
pathoinhibitory actions in congestive heart failure in humans 
remain to be explored. 
Digitalis glycosides, angiotensin-converting enzyme in- 
hibitors and beta-adrenoceptor antagonists may exert part of 
their beneficial ctions in congestive heart failure throu& 
similar mechanisms. Activation of Na+, K+-ATPase at the 
neuronal membrane can cause acute p ripheral baroreceptor 
resetting (112). Di$alis is said to cause a reflex sympathoin- 
hibition that has been attributed to sensitization f cardio- 
pulmonary mechanoreceptors (113) (this observation has 
been disputed [ 1141) and in some subjects with congestive 
heart failure, digitalis normalizes the reflex vasodilator re- 
sponse to cardiac unloading (105). In experimental heart 
failure, ouabain also appears to sensitize arterial barorecep- 
tor nerve endings (38). The effects of long-term treatment 
with digitalis glycosides on sympathetic nerve traEc have 
not been reported. 
Angiotensin-converting e zyme inhibitors (and angioten- 
sin II antsqonisis) improve the parasympathetic control of 
heart rate (115) and should antagonize the facilitative effects 
of angiotensin II on central sympathetic outilow and inhibit 
norepinephrine release at the neuroe&tor junction, where 
it is subject o modulation by prejunctional ngiotensin II 
receptors (26). Despite these potential sympathoinhibitory 
mechanisms, it has been diicult o demonstrate any short- 
term or long-term effect of angiotensin-converting enzyme 
inhibition with enalapril on mean values for plasma norepi- 
nephrine conceWations (101) or any inhibitory eEect of 
acute administration f captopril or enalaprilat ontotal body 
norepinephrine spillover in subjects with congestive heart 
failure (116). Thus, the mechanism ormechanisms respon- 
sible for the beneficial effect of long-term converting enzyme 
inhibition on survival remain open to investigation. 
The role of beta-adrenergic eceptor antagonists in dilated 
cardiomyopathy is discussed elsewhere in this symposium 
(117). In addition to shielding the heart against the poten- 
tially toxic effect of increases inneurally released or circu- 
lating catecholamines (Table 2), this class of drugs may 
dampen central sympathetic outllow (118). An additional 
benefit of beta-blockade may be that proposed by Daly and 
Sole (7): Beta-adrenergic blockade should improve the tem- 
poral coordination of excitation and contraction between 
innervated and denervated segments by restoring the unifor- 
mity of neural stimulation of the heart. 
conclusions * 
The time course over which organ-spectic or generalized 
sympathetic a tivity begins to increase after the develop 
ment of left ventricular dysfunction has not been character- 
ized. Because the primary derangement i  subjects with 
such dysfunction iscardiac, sympathetic drive ta the heart 
may be increased early in the course of this disorder before 
there is any obvious increase in muscle sympathetic burst 
frequency, total body norepinephrine spillover or plasma 
norepinephrine concentration. Activation of adrenergic 
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drive to tin diseased myocardium ay be the causative 
tnechr;lllsm li&ittg sympathetic a tivation to adverse OBt- 
come, and interventions that selectively modulate sympa- 
thetic outtlow to the heart may exert he greatest benefit, 
particularly if administered arly before the development of 
generalixed sympathetic a tivation. In this respect, he re- 
cent observation by Bristow et al. (119) that beta- 
adrenoceptor blockade with carvedilol selectively attenuates 
adrenergic drive to the failing heart is particularly interesting 
and could serve as the basis for future tests of this concept. 
Activation of the sympathetic nervous ystem appears to 
independently predict adverse outcome in patients with left 
ventricular dysfunction, but increased central sympathetic 
outflow is not specific for this condition. It is present inother 
disorders that do not share the dim prognosis ofpatients with 
congestive heart failure. The adverse ffects of adrenergic 
activation on the diseased myocardium ay be a function of 
the magnitude and time course of the increase in cardiac 
sympathetic nerve activity, the mechanical and electrophys- 
iologic onsequences of nonuniform abnormalities ofcat&c 
innervation i the failing heart and the absence of specific 
protective countervailii forces present in other conditions 
also characterized byadrenergic activation. Furthermore, 
not all patients with left ventricular dysfunction have in- 
creased sympathetic nerve activity. Greater understanding 
of the mechanisms responsible for the heterogeneity of 
sympathetic a tivation i response to ventricular dysknc- 
tion, for cardiac-specific and generalized activation of the 
sympathetic nervous ystem and for the stimulation or 
suppression f compensatory mechanisms capable of resist- 
ing its adverse ffects i  fundamental o the development of 
better therapies for congestive h art failure. 
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